IFNA1 and systemic lupus erythematosus: The MUSE study, a trial of anifrolumab, showed that SLE patients with high IFN gene signature (IFNGS) or high disease activity had decreased numbers of lymphocytes, neutrophils, pDCs and monocytes, and the decrease in these cells was reversed after anifrolumab treatment (83).